Henry van den Bedem, PhD

Henry is Chief Technology Officer of Expedition Medicines. 

Henry joined Expedition Medicines in 2025. Prior to joining Expedition Medicines, Henry led the Machine Learning Research & Cheminformatics department at Atomwise as a Senior Vice President. His team developed the AtomNet platform, leveraging novel predictive and generative AI approaches for small molecule drug discovery. Before Atomwise, Henry was a senior staff scientist at the SLAC National Accelerator Laboratory at Stanford University. As Principal Investigator, Henry secured National Institutes of Health funding for his research at SLAC, which also attracted support from the biotech industry and the National Science Foundation. He was also a founding member of SLAC’s Biosciences Department. 

Henry concurrently holds an adjunct associate professor position in Bioengineering and Therapeutic Sciences at the University of California San Francisco. He was a Mercator Fellow at the Friedrich Alexander University at Erlangen, Germany from 2019 – 2020. Henry holds a Ph.D. in Mathematics from the University of Alabama at Birmingham and an MSc (Ir.) in Applied Mathematics from Delft University of Technology, The Netherlands. Henry has (co-)authored more than 150 publications and patents, including articles in Nature, baby Natures, and PNAS, spanning mathematics, machine learning, small molecule drug discovery, and protein sciences.